A Chinese Oncology Company With Great Potential

  • Hutchison China MediTech is a major Chinese company with an established market in that country.
  • Its R&D subsidiary is developing a number of oncology drugs which have shown great potential.
  • The relative ignorance in the US about the company’s potential makes it a great investment right now.

By Dr. Udaya K Maiya, Oncologist, MBBS, MD, DNB, DCCF-Paris

The thesis is quite simple: Hutchison China MediTech Ltd - ADR (NASDAQ:HCM) is a Hong Kong based company with a market cap just shy of $3bn that is partnering with Eli Lilly (LLY) to develop a drug candidate targeting third line metastatic colorectal cancer (mCRC), which, if approved, will bring in peak sales of roughly $250mn per year.

The full post is available to investor members only. Subscribe here.